dronabinol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
cannabinoid receptors agonists 4109 1972-08-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tetrahydrocannabinol
  • THC
  • dronabinol
  • marinol
A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.
  • Molecular weight: 314.47
  • Formula: C21H30O2
  • CLOGP: 7.24
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 29.46
  • ALOGS: -5.08
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.91 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 8.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 33 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 8 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 5.158 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.799 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.321 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 29.992 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 0.090 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 0.080 % High 1
herg hERG pIC50 4.857 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 21.330 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 30.903 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 0.310 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 59
kinase-selectivity-class AXL,EIF2AK3,GRK2 3
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.114 High 1
mh-clint Mouse hepatocyte intrinsic clearance 115.611 High 1
mppb Mouse plasma protein binding (% unbound) 0.280 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.121 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.100 % High 1
rh-clint Rat hepatocyte intrinsic clearance 94.842 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 0.150 % High 1
rppb Rat plasma protein binding (% unbound) 0.260 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 2.254 uM High 1

Approvals:

DateAgencyCompanyOrphan
May 31, 1985 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product temperature excursion issue 125.64 16.59 27 9519 876 90618025
Vascular device infection 124.50 16.59 47 9499 11905 90606996
Nail bed inflammation 92.39 16.59 24 9522 1777 90617124
Nasal mucosal disorder 86.87 16.59 23 9523 1834 90617067
Streptococcal sepsis 80.24 16.59 25 9521 3559 90615342
Pseudomonal sepsis 79.78 16.59 26 9520 4276 90614625
Drug screen positive 79.08 16.59 25 9521 3732 90615169
Nausea 73.25 16.59 269 9277 1110047 89508854
Brain oedema 61.42 16.59 32 9514 17353 90601548
Varicose vein 59.29 16.59 24 9522 7303 90611598
Decreased appetite 56.24 16.59 123 9423 376417 90242484
Failure to thrive 56.09 16.59 24 9522 8387 90610514
Paronychia 53.91 16.59 23 9523 7983 90610918
Dehydration 53.83 16.59 83 9463 194364 90424537
Vomiting 51.76 16.59 191 9355 788102 89830799
Sepsis 51.53 16.59 78 9468 179736 90439165
Product storage error 51.50 16.59 30 9516 20211 90598690
Metastases to lymph nodes 48.54 16.59 24 9522 11665 90607236
Candida infection 48.37 16.59 35 9511 34022 90584879
Death 47.73 16.59 130 9416 456421 90162480
Product prescribing issue 47.45 16.59 21 9525 7958 90610943
Restlessness 46.87 16.59 35 9511 35685 90583216
Intracranial pressure increased 43.99 16.59 19 9527 6792 90612109
Metastases to central nervous system 42.00 16.59 25 9521 17517 90601384
Diarrhoea 40.26 16.59 200 9346 938990 89679911
Hypokalaemia 33.53 16.59 54 9492 131062 90487839
Skin fissures 33.28 16.59 23 9523 20786 90598115
Drug ineffective 32.92 16.59 60 9486 1384238 89234663
Disease progression 32.78 16.59 59 9487 156556 90462345
Pleural effusion 31.23 16.59 48 9498 111943 90506958
Malnutrition 28.48 16.59 20 9526 18538 90600363
Iron deficiency anaemia 28.42 16.59 22 9524 23640 90595261
Joint swelling 28.16 16.59 9 9537 503291 90115610
Toxicity to various agents 28.07 16.59 80 9466 287766 90331135
Hypophagia 27.91 16.59 26 9520 35911 90582990
Eczema 27.82 16.59 31 9515 52839 90566062
Drug abuse 26.86 16.59 38 9508 82309 90536592
Rheumatoid arthritis 25.23 16.59 4 9542 362610 90256291
Soft tissue infection 25.21 16.59 10 9536 2887 90616014
Infusion related reaction 24.12 16.59 7 9539 416773 90202128
COVID-19 23.83 16.59 54 9492 168789 90450112
Glossodynia 23.67 16.59 3 9543 321776 90297125
Plasma cell myeloma 23.33 16.59 25 9521 40803 90578098
Thrombocytopenia 23.32 16.59 61 9485 208664 90410237
Mental status changes 23.17 16.59 26 9520 44653 90574248
Flatulence 23.06 16.59 25 9521 41342 90577559
Drug hypersensitivity 23.05 16.59 10 9536 463599 90155302
Hepatic enzyme increased 22.91 16.59 5 9541 360731 90258170
Asphyxia 22.06 16.59 12 9534 7091 90611810
Gamma-glutamyltransferase increased 21.26 16.59 23 9523 37929 90580972
Back pain 20.80 16.59 77 9469 317098 90301803
Hypersensitivity 20.78 16.59 11 9535 454666 90164235
Urinary tract infection 20.72 16.59 75 9471 305557 90313344
Hyperlipasaemia 19.46 16.59 6 9540 825 90618076
Substance abuse 19.23 16.59 10 9536 5396 90613505
Constipation 19.17 16.59 69 9477 280326 90338575
Defaecation disorder 18.80 16.59 6 9540 923 90617978
Pericarditis 18.74 16.59 3 9543 270148 90348753
Blood bilirubin increased 18.72 16.59 23 9523 43447 90575454
Deep vein thrombosis 18.50 16.59 34 9512 91586 90527315
White blood cell count decreased 17.80 16.59 48 9498 167061 90451840
Fatigue 16.67 16.59 190 9356 1153833 89465068

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 339.56 17.12 240 9500 104531 42507064
Toxicity to various agents 246.21 17.12 281 9459 228855 42382740
Poisoning 161.56 17.12 75 9665 14624 42596971
Drug screen positive 153.53 17.12 51 9689 4080 42607515
Drug dependence 99.29 17.12 69 9671 29025 42582570
Substance abuse 90.30 17.12 43 9697 8862 42602733
Asphyxia 86.86 17.12 41 9699 8285 42603310
Brain oedema 78.45 17.12 48 9692 16279 42595316
Hangover 71.50 17.12 21 9719 1117 42610478
Aggression 64.46 17.12 64 9676 44099 42567496
Overdose 62.58 17.12 97 9643 105167 42506428
Respiratory depression 57.99 17.12 42 9698 18826 42592769
Arteriosclerosis coronary artery 49.41 17.12 38 9702 18639 42592956
Pulmonary oedema 46.40 17.12 59 9681 53213 42558382
Nausea 44.78 17.12 194 9546 396605 42214990
Decreased appetite 40.50 17.12 116 9624 193021 42418574
Product temperature excursion issue 39.67 17.12 11 9729 475 42611120
Failure to thrive 38.48 17.12 25 9715 9397 42602198
Drug level above therapeutic 38.01 17.12 21 9719 5885 42605710
Product prescribing issue 37.96 17.12 22 9718 6751 42604844
Dehydration 37.66 17.12 93 9647 141674 42469921
Muscle mass 36.28 17.12 9 9731 250 42611345
Dysarthria 34.52 17.12 44 9696 39763 42571832
Cardio-respiratory arrest 29.31 17.12 50 9690 58586 42553009
Testicular atrophy 28.34 17.12 9 9731 623 42610972
Drug tolerance 27.70 17.12 14 9726 3276 42608319
Vomiting 27.64 17.12 135 9605 289588 42322007
Rebound effect 26.32 17.12 18 9722 7361 42604234
Myocardial fibrosis 25.65 17.12 10 9730 1265 42610330
Seizure 24.82 17.12 72 9668 120489 42491106
Death 23.67 17.12 186 9554 470999 42140596
Cardiac death 23.05 17.12 9 9731 1143 42610452
Weight decreased 22.82 17.12 101 9639 207847 42403748
Agitation 21.23 17.12 46 9694 64268 42547327
Neuromuscular blockade 19.97 17.12 6 9734 345 42611250
Adrenergic syndrome 19.79 17.12 5 9735 150 42611445
Drug withdrawal syndrome 18.96 17.12 24 9716 21525 42590070
Neonatal infection 18.41 17.12 6 9734 451 42611144
Fatigue 18.14 17.12 165 9575 435476 42176119
Drug screen negative 18.12 17.12 5 9735 212 42611383
Confusional state 18.06 17.12 81 9659 167516 42444079
Accidental overdose 18.05 17.12 27 9713 28303 42583292
Plasma cell myeloma 18.01 17.12 36 9704 47542 42564053
Paradoxical drug reaction 17.95 17.12 12 9728 4726 42606869
Mucosal infection 17.22 17.12 5 9735 255 42611340
Withdrawal syndrome 17.21 17.12 19 9721 14756 42596839

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 357.57 15.32 258 16241 177153 110395647
Toxicity to various agents 288.66 15.32 356 16143 480199 110092601
Drug screen positive 231.62 15.32 70 16429 6340 110566460
Poisoning 160.53 15.32 81 16418 29024 110543776
Brain oedema 155.46 15.32 81 16418 31017 110541783
Substance abuse 123.15 15.32 52 16447 12411 110560389
Asphyxia 110.20 15.32 50 16449 14165 110558635
Vascular device infection 91.17 15.32 46 16453 16466 110556334
Aggression 88.02 15.32 72 16427 59138 110513662
Dehydration 87.97 15.32 153 16346 279358 110293442
Nail bed inflammation 85.66 15.32 25 16474 2005 110570795
Nasal mucosal disorder 83.04 15.32 24 16475 1859 110570941
Failure to thrive 81.40 15.32 40 16459 13534 110559266
Drug dependence 78.95 15.32 63 16436 49957 110522843
Nausea 74.59 15.32 372 16127 1235318 109337482
Streptococcal sepsis 66.74 15.32 26 16473 5046 110567754
Hangover 64.02 15.32 21 16478 2481 110570319
Restlessness 62.58 15.32 58 16441 56201 110516599
Decreased appetite 56.96 15.32 178 16321 475668 110097132
Respiratory depression 56.33 15.32 43 16456 31958 110540842
Pulmonary oedema 55.97 15.32 72 16427 100587 110472213
Varicose vein 55.66 15.32 25 16474 6915 110565885
Pseudomonal sepsis 55.26 15.32 27 16472 9019 110563781
Paronychia 52.90 15.32 28 16471 11053 110561747
Overdose 52.55 15.32 111 16388 233683 110339117
Vomiting 49.77 15.32 267 16232 910408 109662392
Death 48.95 15.32 220 16279 698649 109874151
Arteriosclerosis coronary artery 46.98 15.32 35 16464 25083 110547717
Agitation 45.16 15.32 69 16430 112982 110459818
Dysarthria 41.87 15.32 57 16442 84064 110488736
Hypophagia 39.73 15.32 44 16455 52582 110520218
Drug hypersensitivity 38.72 15.32 10 16489 454080 110118720
Drug level above therapeutic 38.27 15.32 23 16476 11565 110561235
Metastases to lymph nodes 37.54 15.32 25 16474 15007 110557793
Metastases to central nervous system 36.55 15.32 29 16470 22788 110550012
Testicular atrophy 35.86 15.32 9 16490 407 110572393
Muscle mass 34.52 15.32 9 16490 474 110572326
Drug ineffective 34.11 15.32 115 16384 1520425 109052375
Plasma cell myeloma 33.39 15.32 44 16455 62892 110509908
Candida infection 32.60 15.32 38 16461 47971 110524829
Sepsis 32.46 15.32 115 16384 327231 110245569
Hypersensitivity 32.39 15.32 10 16489 403988 110168812
Malnutrition 32.04 15.32 29 16470 27250 110545550
Rheumatoid arthritis 31.10 15.32 4 16495 299609 110273191
Joint swelling 30.43 15.32 14 16485 442831 110129969
Cardio-respiratory arrest 29.56 15.32 58 16441 115778 110457022
Disease progression 28.86 15.32 91 16408 243943 110328857
Fatigue 28.78 15.32 292 16207 1215666 109357134
Mental status changes 28.35 15.32 45 16454 76077 110496723
Skin fissures 26.77 15.32 25 16474 24433 110548367
Seizure 26.63 15.32 83 16416 221102 110351698
Product prescribing issue 26.61 15.32 19 16480 12753 110560047
Infective pulmonary exacerbation of cystic fibrosis 26.33 15.32 20 16479 14751 110558049
Infusion related reaction 26.26 15.32 12 16487 381150 110191650
Lower respiratory tract infection 25.83 15.32 3 16496 243103 110329697
Myocardial fibrosis 25.45 15.32 10 16489 1985 110570815
Intracranial pressure increased 25.06 15.32 17 16482 10518 110562282
Behaviour disorder 23.98 15.32 16 16483 9631 110563169
Cardiac death 23.40 15.32 9 16490 1687 110571113
Hypokalaemia 23.39 15.32 70 16429 182378 110390422
Accidental poisoning 23.31 15.32 10 16489 2477 110570323
Diarrhoea 22.02 15.32 263 16236 1139242 109433558
Weight decreased 22.00 15.32 132 16367 467925 110104875
Rebound effect 21.98 15.32 18 16481 14788 110558012
Pleural effusion 21.68 15.32 67 16432 177642 110395158
Accidental overdose 21.20 15.32 32 16467 51802 110520998
Pericarditis 20.31 15.32 4 16495 219110 110353690
Mucosal infection 20.08 15.32 6 16493 522 110572278
Therapeutic product effect decreased 19.65 15.32 6 16493 244310 110328490
Drug withdrawal syndrome 19.25 15.32 26 16473 38028 110534772
Soft tissue infection 19.13 15.32 11 16488 5096 110567704
Adrenergic syndrome 19.02 15.32 5 16494 272 110572528
Arthralgia 18.77 15.32 57 16442 779575 109793225
Glossodynia 18.69 15.32 5 16494 221999 110350801
Treatment failure 18.67 15.32 9 16490 277225 110295575
Wound 18.42 15.32 6 16493 234431 110338369
Neuromuscular blockade 18.05 15.32 6 16493 738 110572062
Hepatic enzyme increased 17.96 15.32 13 16486 320879 110251921
Maternal exposure during pregnancy 17.58 15.32 8 16491 254875 110317925
Musculoskeletal stiffness 17.49 15.32 10 16489 279812 110292988
Defaecation disorder 17.30 15.32 6 16493 839 110571961
Intentional product misuse 16.10 15.32 50 16449 132854 110439946
Blood cholesterol increased 15.86 15.32 4 16495 184781 110388019
Bradykinesia 15.77 15.32 13 16486 10775 110562025
Paranoia 15.67 15.32 18 16481 22356 110550444
Hypertension 15.58 15.32 33 16466 510051 110062749
Thrombocytopenia 15.49 15.32 97 16402 348788 110224012
Drug intolerance 15.39 15.32 23 16476 406489 110166311
Breast cancer metastatic 15.36 15.32 13 16486 11168 110561632

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A04AD10 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
FDA CS M0003267 Cannabinoids
MeSH PA D000700 Analgesics
MeSH PA D006213 Hallucinogens
MeSH PA D006728 Hormones
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D063386 Cannabinoid Receptor Agonists
FDA EPC N0000175782 Cannabinoid
CHEBI has role CHEBI:25212 metabolites
CHEBI has role CHEBI:35499 hallucinogens
CHEBI has role CHEBI:53000 epitope role
CHEBI has role CHEBI:67072 cannabinoid receptor agonists

Related Drugs by ATC class:

A04AD Other antiemetics 8 drugs
aprepitantcasopitantcerium oxalatechlorobutanolmetopimazinenabilonerolapitantscopolamine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000
Anorexia from HIV indication
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Lowered convulsive threshold contraindication 19260006
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Schizophrenia contraindication 58214004 DOID:5419
Substance abuse contraindication 66214007
Epilepsy contraindication 84757009 DOID:1826
Syncope contraindication 271594007
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.15 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cannabinoid receptor 1 GPCR AGONIST Ki 8.54 CHEMBL CHEMBL
Fatty-acid amide hydrolase 1 Enzyme IC50 4.36 CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 5.89 CHEMBL
Glycine receptor subunit alpha-2 Ion channel ALLOSTERIC MODULATOR EC50 6 IUPHAR
Cannabinoid receptor 2 GPCR Ki 8.48 CHEMBL
Glycine receptor subunit alpha-3 Ion channel ALLOSTERIC MODULATOR EC50 5.30 IUPHAR
N-arachidonyl glycine receptor GPCR EC50 6.02 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.90 IUPHAR
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Enzyme EC50 6.34 CHEMBL
Monoacylglycerol lipase ABHD12 Enzyme IC50 4.94 CHEMBL
Transient receptor potential cation channel subfamily M member 8 Ion channel IC50 6.80 CHEMBL
G-protein coupled receptor 55 GPCR IC50 4.85 CHEMBL
Cannabinoid receptor GPCR Ki 7.39 CHEMBL
L-lactate dehydrogenase A chain Enzyme Ki 4.85 CHEMBL
Monoacylglycerol lipase ABHD6 Enzyme IC50 4.32 CHEMBL
D(3) dopamine receptor GPCR EC50 7.99 CHEMBL
Cannabinoid receptor 1 GPCR Ki 7.43 CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.04 CHEMBL
Cannabinoid receptor 1 GPCR Ki 7.40 CHEMBL
Cannabinoid receptor GPCR Ki 7.34 CHEMBL
Transient receptor potential cation channel subfamily V member 2 Ion channel ACTIVATOR EC50 4.85 IUPHAR

External reference:

IDSource
4018511 VUID
N0000146833 NUI
D00306 KEGG_DRUG
4018511 VANDF
CHEBI:66964 CHEBI
TCI PDB_CHEM_ID
CHEMBL465 ChEMBL_ID
5547 INN_ID
DB00470 DRUGBANK_ID
7J8897W37S UNII
10402 RXNORM
138250 MMSL
1589 MMSL
4645 MMSL
d00866 MMSL
001685 NDDF
010757 NDDF
108415005 SNOMEDCT_US
386846008 SNOMEDCT_US
72024007 SNOMEDCT_US
96225007 SNOMEDCT_US
C0039663 UMLSCUI
D013759 MESH_DESCRIPTOR_UI
16078 PUBCHEM_CID
7J8897W37S INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7144 CAPSULE 2.50 mg ORAL NDA authorized generic 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7145 CAPSULE 5 mg ORAL NDA authorized generic 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-761 CAPSULE 2.50 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-762 CAPSULE 5 mg ORAL ANDA 32 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 17478-763 CAPSULE 10 mg ORAL ANDA 32 sections
SYNDROS HUMAN PRESCRIPTION DRUG LABEL 1 20482-335 SOLUTION 5 mg ORAL NDA 32 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 31722-960 CAPSULE 2.50 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 31722-961 CAPSULE 5 mg ORAL ANDA 19 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 31722-962 CAPSULE 10 mg ORAL ANDA 19 sections
Marinol Human Prescription Drug Label 1 53097-568 CAPSULE 2.50 mg ORAL NDA 29 sections
Marinol Human Prescription Drug Label 1 53097-569 CAPSULE 5 mg ORAL NDA 29 sections
Marinol Human Prescription Drug Label 1 53097-570 CAPSULE 10 mg ORAL NDA 29 sections
MARINOL Human Prescription Drug Label 1 53097-571 CAPSULE 2.50 mg ORAL NDA 29 sections
MARINOL Human Prescription Drug Label 1 53097-572 CAPSULE 5 mg ORAL NDA 29 sections
MARINOL Human Prescription Drug Label 1 53097-573 CAPSULE 10 mg ORAL NDA 29 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 54868-5929 CAPSULE 5 mg ORAL ANDA 22 sections
Dronabinol HUMAN PRESCRIPTION DRUG LABEL 1 62135-033 SOLUTION 5 mg ORAL NDA 20 sections
Dronabinol Human Prescription Drug Label 1 67877-753 CAPSULE 2.50 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Dronabinol Human Prescription Drug Label 1 67877-754 CAPSULE 5 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Dronabinol Human Prescription Drug Label 1 67877-755 CAPSULE 10 mg ORAL NDA AUTHORIZED GENERIC 29 sections
SYNDROS HUMAN PRESCRIPTION DRUG LABEL 1 78613-201 SOLUTION 5 mg ORAL NDA 31 sections
SYNDROS HUMAN PRESCRIPTION DRUG LABEL 1 85776-201 SOLUTION 5 mg ORAL NDA 31 sections
DRONABINOL HUMAN PRESCRIPTION DRUG LABEL 1 85776-202 SOLUTION 5 mg ORAL NDA 31 sections